Reverb Therapeutics uses its proprietary Amplifier technology platform to develop cytokine therapies for oncology and auto-immune diseases with minimal toxicity and maximal efficacy.  David De Graaf, CEO & President, is a serial entrepreneur, having held CEO positions at Abcuro, Comet Therapeutics,  Syntiummune, and Salventa.  His goal is to change the underpinnings of pharmaceutical R&D in order to provide more integrative, personalized patient care in all therapeutic areas.